SiteOne Therapeutics, Inc., a clinical-stage biopharmaceutical company developing new treatments to address conditions involving hypersensitivity of the nervous system, today announced that dosing has commenced in the company’s Phase 1, dose-escalation study of ST-2427, a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain.
| SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/ -- SiteOne Therapeutics Inc., a clinical-stage biopharmaceutical company developing new treatments to address conditions involving hypersensitivity of the nervous system, today announced that dosing has commenced in the company’s Phase 1, dose-escalation study of ST-2427, a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain.
“The initiation of this study represents a significant milestone for the company as it is our first drug candidate to enter the clinic,” stated John Mulcahy, Ph.D., chief executive officer of SiteOne. “There is an urgent, unmet need to develop effective non-opioid therapies for pain. Our lead compound, ST-2427, addresses that need by targeting the peripheral nerve fibers that conduct pain signals without the potential for CNS side effects, addiction and abuse liability of opioid medications.” ST-2427 blocks sodium ion channel 1.7 (NaV1.7). NaV1.7 is a subtype of sodium channel that is highly expressed in peripheral nerve fibers, responsible for pain signal transmission, and is validated as a target for pain treatment by human genetics. Individuals lacking this protein are unable to experience pain. By selectively targeting NaV1.7, ST-2427 aims to stop the electrical signals responsible for pain before they reach the central nervous system. “SiteOne has discovered exquisitely selective modulators of multiple sodium channel subtypes, and we are now advancing development candidates for a number of indications, starting off by addressing acute pain,” said Debra Odink, Ph.D., SiteOne’s chief development officer. “We look forward to working with the medical community to bring the promise of this new approach to patients and anticipate initial data will drive our future development plans.” The phase 1 study is a randomized, double-blind, placebo-controlled study in healthy adults to evaluate the safety, tolerability, and pharmacokinetics of ST-2427. The study is enrolling subjects at AltaSciences in Overland Park, Kansas. Subjects in each group will be randomized to receive a single dose of ST-2427 or placebo. Additionally, SiteOne recently announced the expansion its technology platform and clinical development activities to address hypersensitivity disorders more broadly in both the peripheral and central nervous systems. These disorders include chronic cough, neuropathic pain, ocular discomfort, and pruritus. About the ST-2427 Phase 1 Study About ST-2427 About SiteOne Therapeutics Media Contacts: Evan Wicker, Ph.D.
SOURCE SiteOne Therapeutics |
View original content to download multimedia:
